Marfella et al. [129] showed that the DPP-4 inhibitor vildagliptin (administered at the dose of 50 mg twice daily) may accelerate the healing of chronic foot ulcers in patients with T2D by enhancing angiogenesis (as evidenced by increased ulcer capillary density and VEGF expression levels) and reducing the levels of nitrotyrosine (a marker of oxidative stress) within the ulcer specimens. The gene discussed is DPP4; the disease is ulcer disease.